Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | ADH5 | P11766 | 1/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30558759 | 0.84 | ALDH1A1 (0.71) | ALDH1A1CYP3A4CYP1A2CYP2D6CYP19A1 | |
| SCHEMBL300802 | 0.84 | CYP3A4 (0.61) | ALDH1A1CYP3A4CYP1A2CYP2D6CYP19A1 | |
| SCHEMBL111365 | 0.83 | CYP3A4 (0.53) | ALDH1A1CYP3A4CYP1A2CYP2D6CYP19A1 | |
| SCHEMBL7809131 | 0.82 | ALDH1A1 (0.56) | ALDH1A1CYP3A4CYP1A2CYP2D6CYP19A1 | |
| SCHEMBL7802849 | 0.82 | ALDH1A1 (0.56) | ALDH1A1CYP3A4CYP1A2CYP2D6CYP19A1 | |
| Hydrochloric Acid SCHEMBL7809105 | 0.81 | ALDH1A1 (0.54) | ALDH1A1CYP3A4CYP1A2CYP2D6CYP19A1 | |
| SCHEMBL6425285 | 0.80 | KEAP1 (0.43) | ALDH1A1CYP3A4CYP1A2CYP2D6CYP19A1 | |
| SCHEMBL265184 | 0.79 | ALDH1A1 (0.61) | ALDH1A1CYP3A4CYP1A2CYP2D6CYP19A1 | |
| SCHEMBL15094392 | 0.79 | ALDH1A1 (0.53) | ALDH1A1CYP3A4CYP1A2CYP2D6CYP19A1 | |
| SCHEMBL8268417 | 0.79 | ALDH1A1 (0.65) | ALDH1A1CYP3A4CYP1A2CYP2D6CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116751430-A | Self-repairing elastomer based on triple hydrogen bond and metal coordination effect and preparation method thereof | 西北工业大学 | 2023-09-15 | — | — | CN | claimed |
| US-20240383900-A1 | SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2024-11-21 | — | — | US | disclosed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| CN-117940427-A | Substituted pyrazolo [1,5-a ] pyrimidine-7-amine compounds as CDK inhibitors and therapeutic uses thereof | 卡里克治疗有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4355426-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2024-04-24 | — | — | EP | disclosed |
| US-11795163-B2 | Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same | CHECKMATE THERAPEUTICS INC. | 2023-10-24 | — | — | US | disclosed |
| US-11795163-B2 | Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same | CHECKMATE THERAPEUTICS INC. | 2023-10-24 | — | — | US | disclosed |
| CN-116751430-A | Self-repairing elastomer based on triple hydrogen bond and metal coordination effect and preparation method thereof | 西北工业大学 | 2023-09-15 | — | — | CN | disclosed |
| US-20230010258-A1 | COMPOSITION FOR PREVENTING OR INHIBITING AXONAL DEGENERATION | CHECKMATE THERAPEUTICS INC. (KR) | 2023-01-12 | — | — | US | disclosed |
| WO-2022263604-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2022-12-22 | — | — | WO | disclosed |
| US-20090253670-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2009-10-08 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| EP-2094677-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV Remynd (BE) | 2009-09-02 | — | — | EP | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| WO-2008061781-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008009077-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009078-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009076-A2 | SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008003149-A2 | SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES , INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | ALDH1A1 2743/4885CYP3A4 256/4885CYP1A2 1131/4885 |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885CYP3A4 3900/4885CYP1A2 2850/4885 |
| US-20230010258-A1 | COMPOSITION FOR PREVENTING OR INHIBITING AXONAL DEGENERATION | BDNF, GAP43, PRPH | ALDH1A1 2290/4885CYP3A4 4882/4885CYP1A2 4852/4885 |
| US-20090253696-A1 | SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | PNPO, PNP, DPYD | ALDH1A1 1721/4885CYP3A4 57/4885CYP1A2 115/4885 |
| US-20240383900-A1 | SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CDK3, CDK1, CDK2 | ALDH1A1 4701/4885CYP3A4 3444/4885CYP1A2 2735/4885 |
| US-20090253670-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | CHRNA4, CHRNA2, CHRNA3 | ALDH1A1 4162/4885CYP3A4 3973/4885CYP1A2 4439/4885 |
| US-11795163-B2 | Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same | NAMPT, NAPRT, NNT | ALDH1A1 1903/4885CYP3A4 4056/4885CYP1A2 3970/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ALDH1A1 1930/4885CYP3A4 3900/4885CYP1A2 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.